OBJECTIVE: To determine whether smoking or alcohol use impacts the age of onset and disease duration in multiple system atrophy (MSA). METHODS: All patients diagnosed with MSA at Mayo Clinic, Rochester between 1998 and 2012 completed standardized questionnaires surveying smoking and alcohol use at the time of presentation. RESULTS: Of 551 patients with smoking and alcohol use data, 281 were past or present smokers with age of onset of 60.76 years compared to 62.97 years in controls (p = 0.0144). Age of onset in the 87 heavy alcohol users was 56.87 years compared to 62.97 years in controls (p = 0.0133). There was no difference in disease duration for smokers (p = 0.2758) or heavy alcohol users (p = 0.4820) compared to controls. CONCLUSION: Our findings show that smoking history and/or heavy alcohol use is associated with younger age of onset in MSA but do not influence survival.
OBJECTIVE: To determine whether smoking or alcohol use impacts the age of onset and disease duration in multiple system atrophy (MSA). METHODS: All patients diagnosed with MSA at Mayo Clinic, Rochester between 1998 and 2012 completed standardized questionnaires surveying smoking and alcohol use at the time of presentation. RESULTS: Of 551 patients with smoking and alcohol use data, 281 were past or present smokers with age of onset of 60.76 years compared to 62.97 years in controls (p = 0.0144). Age of onset in the 87 heavy alcohol users was 56.87 years compared to 62.97 years in controls (p = 0.0133). There was no difference in disease duration for smokers (p = 0.2758) or heavy alcohol users (p = 0.4820) compared to controls. CONCLUSION: Our findings show that smoking history and/or heavy alcohol use is associated with younger age of onset in MSA but do not influence survival.
Authors: N Vanacore; V Bonifati; G Fabbrini; C Colosimo; R Marconi; D Nicholl; U Bonuccelli; F Stocchi; P Lamberti; G Volpe; G De Michele; I Iavarone; P Bennett; P Vieregge; G Meco Journal: Neurology Date: 2000-01-11 Impact factor: 9.910
Authors: Jordan L Schultz; John A Kamholz; David J Moser; Shawna M E Feely; Jane S Paulsen; Peg C Nopoulos Journal: Neurology Date: 2017-02-01 Impact factor: 9.910
Authors: Elizabeth A Coon; David M Sletten; Mariana D Suarez; Jay N Mandrekar; J Eric Ahlskog; James H Bower; Joseph Y Matsumoto; Michael H Silber; Eduardo E Benarroch; Robert D Fealey; Paola Sandroni; Phillip A Low; Wolfgang Singer Journal: Brain Date: 2015-09-13 Impact factor: 13.501
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Priya D Shanmugarajah; Nigel Hoggard; Stuart Currie; Daniel P Aeschlimann; Pascale C Aeschlimann; Dermot C Gleeson; Mohammed Karajeh; Nicola Woodroofe; Richard A Grünewald; Marios Hadjivassiliou Journal: Cerebellum Ataxias Date: 2016-10-03
Authors: Stuart J McCarter; Elizabeth A Coon; Rodolfo Savica; Erik K St Louis; James H Bower; Eduardo E Benarroch; Paola Sandroni; Phillip Low; Wolfgang Singer Journal: Mov Disord Date: 2020-04-22 Impact factor: 10.338